期刊文献+

药品生产过程中偏差的分类研究 被引量:3

Research on the Classification of Deviations in Drug Production
原文传递
导出
摘要 目的:研究药品生产过程中偏差的分类。方法:从显性偏差和隐性偏差两个角度,结合风险管理理论,借助不同的风险管理工具对偏差进行风险评估,以界定偏差的严重程度,并采用不同的方法进行处理。结果与结论:根据实际管理过程中偏差的可识别性,可将偏差分为显性偏差和隐性偏差。对于显性偏差,可进行深、浅两个层次的分类;在进行浅层次分类后,判断是否可以明确偏差的发生原因及预估其后果,将偏差进一步分为简单偏差和复杂偏差;对于复杂偏差,可借助风险管理工具进行评估,界定偏差的严重程度。对于隐性偏差,需要事前预防,直接借助风险管理工具进行评估以界定偏差等级,为预防措施提供依据。在偏差的管理过程中,关键在于依靠科学的方法对偏差进行识别、分类和对影响等级进行划分。而结合风险管理理论,进行风险工具的选择和使用是解决该问题的有效途径。 OBJECTIVE:To study the classification of deviation in drug production.METHODS:From the perspective of dominant and hidden deviation,combining with the theory of risk management,risk of deviation was evaluated with different risk management tools to define the severity of the deviation,and it was handled by different methods.RESULTS CONCLUSIONS:According to the identifiability of deviation in actual management,the deviation was divided into dominance and hidden deviation.The dominant deviation can be divided into deep and shallow level.Whether the causes of deviation could be cleared and the consequences could be estimates were judged after the shallow level classification,and the deviation was further divided into simple and complex deviation.As for deviation complex,it could be evaluated with the tools of risk management to define the deviation severity.As for hidden deviation,it needed beforehand preventing with the tools of risk management directly to define deviation levels and provide reference for preventive measures.In the process of deviation management,key point is to relay on the scientific method to identify and classify deviation,and divide the influence levels.Combining the theory of risk management to select and use risk tools is the effective way to solve the problem.
出处 《中国药房》 CAS 北大核心 2015年第19期2601-2604,共4页 China Pharmacy
关键词 药品生产 偏差 分类 风险管理工具 Drug production Deviation Classification Risk management tools
  • 相关文献

参考文献9

  • 1Panagiotou G.The impact of managerial cognitions on the structure-conduct-performance(SCP)paradigm A strategic group perspective[J].Management Decision,2006,44(3):423.
  • 2冷杉.宜春市医药产业的升级和发展研究:基于产业结构视角[J].时代金融,2013(5):107.
  • 3褚淑贞,朱艳梅,陈玉莹.江苏省11个地级市医药产业经济效益差异性分析[J].中国药房,2013,24(13):1153-1156. 被引量:6
  • 4曹阳,洪亮,宋文,茅宁莹.中国生物医药产业SCP分析[J].中国新药杂志,2013,22(4):411-416. 被引量:16
  • 5钟可芬.2013年度中国制药工业百强市场集中度[EB/OL].(2014-05-26)[2015-02-20].http://drug.39.net/qgydz/140527/4395640.html.
  • 6曹军伟.中国医药产业的SCP分析[J].中国药业,2005,14(12):3-4. 被引量:10
  • 7国家发展改革委.国家发展改革委关于调整《国家发展改革委定价药品目录》等有关问题的通知[EB/OL].[2010-03-05].http://bgt.ndrc.gov.cn/zcfb/201003/t20100323_498727.html.
  • 8苏会燕.医药品网络广告2012全年投放纵览[J].中国药店,2013(5):62-62. 被引量:2
  • 9孙炎.医药行业并购高潮迭起医疗器械成PE竞逐最佳标的[EB/OL].(2013-08-30)[2015-02-20].http://news.xinhuanet.com/fortune/2013-08/30/c_125281718.htm.

二级参考文献24

共引文献26

同被引文献20

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部